Rock Springs Capital Management LP Myovant Sciences Ltd. Transaction History

Rock Springs Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$20.46 - $25.18 $10.5 Million - $13 Million	-515,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $31,588 - $63,222	2,289 Added 0.45%	515,000 $14.2 Million
Q3 2020 Nov 16, 2020	BUY	$14.05 - $22.6 $60,415 - $97,180	4,300 Added 0.85%	512,711 $7.2 Million
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $61,736 - $175,285	8,411 Added 1.68%	508,411 $10.5 Million
Q4 2019 Feb 14, 2020	BUY	$4.2 - $19.21 $210,000 - $960,500	50,000 Added 11.11%	500,000 $7.76 Million
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $890,725 - $2.56 Million	102,500 Added 29.5%	450,000 $4.07 Million
Q3 2018 Nov 14, 2018	BUY	$19.33 - $26.78 $1.01 Million - $1.4 Million	52,400 Added 17.76%	347,500 $9.23 Million
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $2.93 Million - $4.57 Million	295,100	295,100 $4.57 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.